english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Opioids: endocrine disruptors

 Adverse Effects  Data from clinical trials, cohort studies and other sources show that opioids also have several endocrine effects, usually in the form of a hormone insufficiency, by acting on the hypothalamic-pituitary axis.
Full article (3 pages) available for download by subscribers.
1 December 2022

Impending changes to European pharmaceutical regulations: part 1

 ADVANCING HEALTHCARE POLICY  In 2020, the European Commission announced its new "Pharmaceutical Strategy for Europe" for the coming years. The new legislation is due to be published in 2023.
Full article (3 pages) available for free download.
1 December 2022

Nivolumab (Opdivo°) as adjuvant treatment for certain oesophageal cancers

 Marketing Authorisations  No proven increase in survival, as of mid-2022, in a double-blind randomised placebo-controlled trial in 794 patients. Longer time before relapse, but with adverse effects that are sometimes serious.
Full article (1 page) available for download by subscribers.
1 December 2022

Bivalent mRNA covid-19 vaccines that also target the Omicron variant: more antibodies

 Marketing Authorisations  Four bivalent messenger RNA (mRNA) vaccines, based on the first Sars-CoV-2 strain isolated and a strain of the Omicron variant of this virus, have been authorised in the European Union. How do Prescrire's editors rate these vaccines?
Full article (2 pages) available for download by subscribers.
1 December 2022

Risdiplam (Evrysdi°) in spinal muscular atrophy. Continue the evaluation

FEATURED REVIEW Risdiplam has been authorised in the European Union for use in patients aged 2 months or older with spinal muscular atrophy. How do Prescrire's editors rate this drug in this situation?
Full review (3 pages) available for download by subscribers.
1 November 2022

A change of paradigm

 Editorial  It is time to extricate ourselves from the paradigm in which drugs are the mainstay of our response to health problems, and to embrace one in which they are just one option rather than an automatic reflex.
1 November 2022

Liraglutide (Saxenda°) in obesity in adolescents: not acceptable

Liraglutide is authorised for use in patients with type 2 diabetes and in obese adults. Its marketing authorisation has now been extended to include obese adolescents.
1 November 2022

Cannabidiol (Epidyolex°) in epilepsy associated with tuberous sclerosis complex

Cannabidiol, a substance present in cannabis, has antiepileptic properties. Having already been authorised in the European Union for children with certain severe forms of epilepsy, it has now also been authorised for use in patients aged 2 years and older who have epileptic seizures associated with tuberous sclerosis complex.
1 November 2022

Messenger RNA covid-19 vaccines: an update on adverse effects

 COVID-19  Two messenger RNA (mRNA) covid-19 vaccines, tozinameran (Comirnaty° from the pharmaceutical companies Pfizer and BioNTech) and elasomeran (Spikevax° from Moderna), have been marketed in the European Union since late 2020. What is known, as of mid-2022, about the adverse effects of these mRNA covid-19 vaccines?
1 November 2022

Etifoxine: a dangerous drug still on the market

The European reassessment of etifoxine, a dangerous drug with no demonstrated efficacy, has only led to some modifications of the summary of product characteristics (SmPC) and the package leaflet.
1 November 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90